Join us for a virtual KOL event with Lumos Pharma, featuring Fernando Cassorla, MD (University of Chile) and Michael Tansey, MD (University of Iowa) who will discuss the therapeutic potential for LUM-201 following their presentations at ENDO, and the role a new oral alternative would play in treating pediatric growth hormone deficiency (PGHD).

Lumos Pharma leadership will also provide a post-ENDO update on the ongoing Phase 2 trial with LUM-201, which is expected to have a final data readout in Q4. If approved by the FDA, LUM-201 would be the first orally administered alternative to recombinant growth hormone injections that PGHD patients endure for years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU.

A live question and answer session will follow the formal presentations.